Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 20, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 1,715,000 ordinary shares.
- Purchase Price: 1,335.3535 pence per share.
- Treasury Shares Held: 401,717,158 shares (representing 7.14% of total voting rights).
- Shares in Issue: 5,621,849,784 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury share holdings following the September 20, 2007 transaction. Consequently, the total number of shares in issue (excluding Treasury shares) is confirmed at 5,621,849,784, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares in issue (5,621,849,784) for compliance with disclosure thresholds.
- Confirm the updated Treasury share count (401,717,158) and its impact on voting rights (7.14%).
- Review the specific price paid (1,335.3535 pence) for the 1,715,000 shares repurchased on September 20, 2007.